Clarification
The Exchange had sought clarification from Cadila Healthcare Ltd with reference to the media report, "Kerala regulator finds three drugs to be of substandard quality" The Company response is enclosed.12-11-2018
12-11-2018
Clarification sought from Cadila Healthcare Ltd
The Exchange has sought clarification from Cadila Healthcare Ltd with respect to news article appearing on indianexpress.com - November 11, 2018 titled "Kerala regulator finds three drugs to be of substandard quality".The reply is awaited.12-11-2018
Zydus Cadila gets USFDA nod for anti-fungal ointment
Zydus Cadila has received final approval from the US health regulator to market Nystatin and Triamcinolone Acetonide ointment, used in the treatment12-11-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Nystatin and Triamcinolone Acetonide Ointment USP12-11-2018
Cadila Healthcare posts 17% dip in Q2 net to Rs 4.1 bn; revenue down 8.1%
Ebitda dipped 20% YoY to Rs 6.87 billion03-11-2018
Unaudited Financial Results For The Quarter / Half Year Ended On September, 2018
Unaudited financial results for the quarter / half year ended on September, 2018 along with limited review report of the Statutory Auditors.03-11-2018
Unaudited Financial Results For The Quarter / Half Year Ended On September 30, 2018
Please find attached the unaudited financial results of the Company for the quarter / half year ended on September 30, 2018 together with the Limited Review Report of the Statutory Auditors.03-11-2018
Zydus Cadila launches generic erectile dysfunction drug in US market
Zydus Cadila has launched generic Vardenafil Hydrochloride tablets used for the treatment of erectile dysfunction in the American market.According to01-11-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Vardenafil Hydrochloride tablets and Ursodiol tablets01-11-2018
Announcement under Regulation 30 (LODR)-Acquisition
'Further to our letters dated August 13, 2018 and October 1, 2018, we hereby inform that the Company has subscribed 51% shares of Windlas Healthcare Private Limited (Windlas) as per the Share Purchase Agreement executed by the Company and Windlas. In view of the above, Windlas has become a subsidiary of the Company. This disclosure is made pursuant to Regulation 30(7) of the SEBI Listing Regulations, 2015....29-10-2018